XML 16 R6.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Balance, beginning of period (in shares) at Dec. 31, 2023   81,767,263      
Balance, beginning of period at Dec. 31, 2023 $ 349,097 $ 8 $ 1,580,241 $ 198 $ (1,231,350)
Statement of Stockholders' Equity (Deficit)          
Exercise of stock options (in shares)   21,975      
Exercise of stock options 192   192    
Vesting of restricted common stock awards (in shares)   445,713      
Stock-based compensation expense 7,585   7,585    
Unrealized (loss) gain on marketable debt securities (524)     (524)  
Net loss (61,950)       (61,950)
Balance, end of period (in shares) at Mar. 31, 2024   82,234,951      
Balance, end of period at Mar. 31, 2024 294,400 $ 8 1,588,018 (326) (1,293,300)
Balance, beginning of period (in shares) at Dec. 31, 2023   81,767,263      
Balance, beginning of period at Dec. 31, 2023 349,097 $ 8 1,580,241 198 (1,231,350)
Statement of Stockholders' Equity (Deficit)          
Unrealized (loss) gain on marketable debt securities 324        
Net loss (191,698)        
Balance, end of period (in shares) at Sep. 30, 2024   82,538,624      
Balance, end of period at Sep. 30, 2024 175,634 $ 8 1,598,152 522 (1,423,048)
Balance, beginning of period (in shares) at Mar. 31, 2024   82,234,951      
Balance, beginning of period at Mar. 31, 2024 294,400 $ 8 1,588,018 (326) (1,293,300)
Statement of Stockholders' Equity (Deficit)          
Vesting of restricted common stock awards (in shares)   121,643      
Issuance of common stock under employee stock purchase plan (in shares)   72,920      
Issuance of common stock under employee stock purchase plan 322   322    
Stock-based compensation expense 5,010   5,010    
Unrealized (loss) gain on marketable debt securities (116)     (116)  
Net loss (67,607)       (67,607)
Balance, end of period (in shares) at Jun. 30, 2024   82,429,514      
Balance, end of period at Jun. 30, 2024 232,009 $ 8 1,593,350 (442) (1,360,907)
Statement of Stockholders' Equity (Deficit)          
Vesting of restricted common stock awards (in shares)   109,110      
Stock-based compensation expense 4,802   4,802    
Unrealized (loss) gain on marketable debt securities 964     964  
Net loss (62,141)       (62,141)
Balance, end of period (in shares) at Sep. 30, 2024   82,538,624      
Balance, end of period at Sep. 30, 2024 175,634 $ 8 1,598,152 522 (1,423,048)
Balance, beginning of period (in shares) at Dec. 31, 2024   82,734,696      
Balance, beginning of period at Dec. 31, 2024 134,274 $ 8 1,602,441 268 (1,468,443)
Statement of Stockholders' Equity (Deficit)          
Issuance of common stock from at the market equity offering, net (in shares)   706,236      
Issuance of common stock from at-the-market equity offering, net 1,435   1,435    
Vesting of restricted common stock awards (in shares)   268,604      
Stock-based compensation expense 2,979   2,979    
Unrealized (loss) gain on marketable debt securities (180)     (180)  
Net loss (76,088)       (76,088)
Balance, end of period (in shares) at Mar. 31, 2025   83,709,536      
Balance, end of period at Mar. 31, 2025 62,420 $ 8 1,606,855 88 (1,544,531)
Balance, beginning of period (in shares) at Dec. 31, 2024   82,734,696      
Balance, beginning of period at Dec. 31, 2024 134,274 $ 8 1,602,441 268 (1,468,443)
Statement of Stockholders' Equity (Deficit)          
Unrealized (loss) gain on marketable debt securities (268)        
Net loss (154,440)        
Balance, end of period (in shares) at Sep. 30, 2025   93,264,421      
Balance, end of period at Sep. 30, 2025 13,453 $ 9 1,636,327 0 (1,622,883)
Balance, beginning of period (in shares) at Mar. 31, 2025   83,709,536      
Balance, beginning of period at Mar. 31, 2025 62,420 $ 8 1,606,855 88 (1,544,531)
Statement of Stockholders' Equity (Deficit)          
Issuance of common stock from at the market equity offering, net (in shares)   3,419,836      
Issuance of common stock from at-the-market equity offering, net 7,185 $ 1 7,184    
Vesting of restricted common stock awards (in shares)   102,894      
Issuance of common stock under employee stock purchase plan (in shares)   156,159      
Issuance of common stock under employee stock purchase plan 228   228    
Stock-based compensation expense 2,664   2,664    
Unrealized (loss) gain on marketable debt securities (73)     (73)  
Net loss (53,235)       (53,235)
Balance, end of period (in shares) at Jun. 30, 2025   87,388,425      
Balance, end of period at Jun. 30, 2025 19,189 $ 9 1,616,931 15 (1,597,766)
Statement of Stockholders' Equity (Deficit)          
Issuance of common stock from at the market equity offering, net (in shares)   5,799,178      
Issuance of common stock from at-the-market equity offering, net 17,147   17,147    
Exercise of stock options (in shares)   12,130      
Exercise of stock options 21   21    
Vesting of restricted common stock awards (in shares)   64,688      
Stock-based compensation expense 2,228   2,228    
Unrealized (loss) gain on marketable debt securities (15)     (15)  
Net loss (25,117)       (25,117)
Balance, end of period (in shares) at Sep. 30, 2025   93,264,421      
Balance, end of period at Sep. 30, 2025 $ 13,453 $ 9 $ 1,636,327 $ 0 $ (1,622,883)